FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Subscribe To Our Newsletter & Stay Updated